Membranoproliferative glomerulonephritis and light-chain nephropathy in association with chronic lymphocytic leukemia.

Mutluay R., Aki S. Z., Erten Y., Konca C., Yagci M., Barit G., ...More

Clinical nephrology, vol.70, no.6, pp.527-31, 2008 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 70 Issue: 6
  • Publication Date: 2008
  • Doi Number: 10.5414/cnp70527
  • Journal Name: Clinical nephrology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.527-31
  • Keywords: chronic lymphocytic leukemia, membranoproliferative glomerulonephritis, light-chain nephropathy, NEPHROTIC SYNDROME, MIXED CRYOGLOBULINEMIA, RITUXIMAB, THERAPY, PATIENT, CYCLOPHOSPHAMIDE, FLUDARABINE, LYMPHOMAS, RESISTANT, KIDNEY
  • Gazi University Affiliated: Yes


The incidence of nephrotic syndrome co-existing with chronic lymphocytic leukemia (CLL) is a rare condition. Almost any glomerular pathology may accompany CLL. The most frequent of all is membranoproliferative glomerulonephritis (MPGN). Moreover, in 5 - 10% of patients with CLL, monoclonal gammopathy may be detected in serum and/or urine samples. There are no well-established treatment protocols for those CLL patients with accompanying nephrotic syndrome. In this case report, we present a 55-year-old female patient diagnosed with CLL, developing nephrotic syndrome, renal dysfunction and IgG kappa-type monoclonal gammopathy in the follow-up. The renal biopsy revealed glomerular and tubular deposits of kappa-chain and histopathology of membranoproliferative glomerulonephritis. Rituximab along with CVP (cyclophosphamide - vincristine - prednisolone) chemotherapy regimen was initiated. At the end of 6 courses of treatment, the patient was on "nephrologic" partial remission as the serum creatinine and albumin levels had returned to normal and proteinuria decreased by more than 50%. The patient was also in partial remission for CLL. In conclusion, in patients with CLL and nephrotic syndrome, presence of MPGN along with light-chain nephropathy is rarely reported. Several different treatment protocols are discussed for these patients. Among these regimes, R-CVP is an acceptable alternative for CLL patients with MPGN.